Loading…
Chinese molecular diagnostics company selling PCR reagents and instruments for infectious-disease and other testing.
Chinese molecular diagnostics company selling PCR reagents and instruments for infectious-disease and other testing.
Sells PCR test kits (reagents) plus the machines that run them; because reagents are generally tied to the instruments they run on, an installed instrument keeps pulling reagent orders. Sales jumped during the COVID-19 testing wave of 2020 to 2022 and then fell back as it turned to other disease areas and overseas markets.
In one line: A Chinese QIAGEN for molecular (PCR) diagnostics.
Moat: narrow (installed base, regulatory licence). Instrument-reagent lock-in and disease-testing registrations favor an incumbent supplier.
Headquarters: Changsha, Hunan, China · Employees: 2,128
Size Sansure Biotech (688289.SS) is a China Health Care company (Medical Specialties) with a market value of $1.36B, the 1783rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥15.79 on 6 Nov 2026.
Performance Over six months the shares fell 7.9%, against -6.9% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 1.2% over the last twelve months (peer median +10.4%); the operating margin is 1.5% (peer median 5.7%).
Valuation It trades at 39.0× forward earnings against a peer median of 23.6× (5th most expensive of 16).
Capital Return on invested capital runs 2.5 points below its cost of capital (5.7% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.65B | CN¥1.64B | CN¥1.45B | CN¥1.00B | CN¥6.42B |
| Revenue growth | — | +13% | +45% | -84% | — |
| Gross profit | CN¥1.24B | CN¥1.08B | CN¥999M | CN¥621M | CN¥3.69B |
| EBITDA | n/a | CN¥364M | CN¥296M | CN¥119M | CN¥2.28B |
| Net income | CN¥112M | CN¥199M | CN¥276M | CN¥364M | CN¥1.94B |
| Free cash flow | -CN¥109M | -CN¥179M | -CN¥132M | -CN¥279M | CN¥2.09B |
| Capital expenditure | CN¥351M | CN¥370M | CN¥421M | CN¥391M | CN¥559M |
| Total debt | CN¥1.54B | CN¥1.16B | CN¥444M | CN¥95.4M | CN¥27.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sansure Biotech 688289.SS | $1.36B | -8% | -1% | 1% | 39.0× | n/a |
| Qiagen QGEN | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% |
| BGI Genomics 300676.SZ | $2.39B | -4% | 0% | -14% | 142.2× | n/a |
| Beijing Hotgen Biotech 688068.SS | $966M | -38% | +8% | -94% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688289.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | +5.7% | 6th lowest of 21 |
| 6-month return | -7.9% | -6.9% | 11th highest of 21 |
| Distance from 52-week high | -31.2% | -34.3% | 10th highest of 21 |
| Revenue growth (TTM) | -1.2% | +10.4% | 3rd lowest of 20 |
| Operating margin | 1.5% | 5.7% | 5th lowest of 20 |
| Forward P/E | 39.0× | 23.6× | 5th most expensive of 16 |
| ROIC minus cost of capital | -2.5 pp | +0.2 pp | 8th lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sansure Biotech 688289.SS | China | $1.36B | -8% | -1% | 1% | 39.0× | n/a | n/a |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.31B | -51% | +132% | 2% | 130.1× | n/a | n/a |
| Sonoscape Medical 300633.SZ | China | $1.42B | -8% | +18% | 4% | 36.8× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.42B | +8% | +15% | 19% | 16.3× | 2.2% | +19.7% |
| Ovctek China 300595.SZ | China | $1.42B | -26% | 0% | 28% | 20.8× | 9.9% | +16.5% |
| El.En ELN.MI | Italy | $1.44B | +11% | +3% | 15% | 21.8× | 9.8% | +7.7% |
| Suzhou Sepax Technologies 688758.SS | China | $1.45B | +19% | +28% | 40% | 50.8× | 24.7% | +23.6% |
| Alpha Tau Medical DRTS | United States | $1.27B | +61% | n/a | n/a | n/a | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.27B | -15% | +21% | 16% | 25.2× | 10.8% | +40.3% |
| STAAR Surgical STAA | United States | $1.26B | -6% | +51% | 18% | 45.8× | n/a | n/a |
| Beijing Balance Medical Technology 688198.SS | China | $1.47B | -26% | +10% | 28% | 46.6× | 22.6% | +27.6% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.26B | +58% | -29% | -74% | n/a | n/a | n/a |
| CLASSYS 214150.KS | South Korea | $1.25B | -54% | +25% | 46% | 12.1× | -8.7% | +34.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.24B | -25% | -6% | 18% | 27.0× | 12.7% | -3.5% |
| CONMED CNMD | United States | $1.53B | +40% | +2% | 2% | 11.1× | 32.4% | +9.8% |
| NovoCure NVCR | United States | $1.55B | -26% | +13% | -17% | n/a | n/a | n/a |
| NIPRO 8086.T | Japan | $1.55B | -9% | +3% | 6% | 14.9× | n/a | n/a |
| Enovis ENOV | United States | $1.57B | +2% | +5% | 3% | 7.7× | 22.3% | -6.0% |
| PROCEPT BioRobotics PRCT | United States | $1.18B | -19% | +23% | -34% | n/a | n/a | n/a |
| Tandem Diabetes Care TNDM | United States | $1.18B | +9% | +4% | -4% | n/a | n/a | n/a |
| Sinocare 300298.SZ | China | $1.58B | +15% | +7% | 6% | 23.6× | 10.8% | +18.3% |